| |
| Featured
Landmark Study - Lifestyle and Obesity Management |
|
STRADIVARIUS: Effect of Rimonabant
on Progression of Atherosclerosis in Patients with Abdominal
Obesity and Coronary Artery Disease. The STRADIVARIUS randomized
controlled trial
OUTCOME
- Progression of coronary
atherosclerosis as assessed by intravascular ultrasound
(IVUS).
TOTAL ENROLLMENT
- 839 patients with abdominal
obesity associated with current smoking and/or metabolic
syndrome, and angiographic evidence of coronary heart disease.
COMPARISONS
- Rimonabant 20 mg/d
vs placebo.
STUDY DESIGN
- Randomized, double-blind,
placebo control, parallel assignment.
|
| Featured
2009 Ongoing Trial - Hypoglycaemic Agents |
|
RECORD: Rosiglitazone Evaluated
for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
OUTCOME
- Time to reach the combined
endpoint of cardiovascular death and/or cardiovascular
hospitalization.
NUMBER OF PATIENTS RANDOMIZED
- 4458 type 2 diabetes
patients (7% < HbA1c < 9%); oral glucose
lowering agent for a minimum of 6 months prior to screening
and unchanged for 2 months prior to screening; BMI > 25.0
kg/m2.
COMPARISONS
- Add-on rosiglitazone,
metformin or sulphonylurea, with dose titration to a target
HbA1c
of < 7%. If confirmed HbA1c
rises to > 8.5%,
either third glucose-lowering drug added (rosiglitazone-treated
group) or insulin started (non-rosiglitazone group). Same
criterion for failure of triple oral drug therapy in the
rosiglitazone-treated group used for starting insulin in
this group.
STUDY DESIGN
- Randomized, open label,
active control, parallel assignment.
|
|
|
